Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Glucosamine No Help for Osteoarthritic Knee Pain

By HospiMedica International staff writers
Posted on 25 Mar 2014
The popular dietary supplement glucosamine shows no evidence of structural benefits among patients with chronic knee pain typical of osteoarthritis (OA), according to a new study.

Researchers at the University of Utah (Salt Lake City, USA), the University of Arizona (Tucson, USA), and other institutions conducted a randomized, double-blind placebo-controlled trial that enrolled 201 participants with mild to moderate pain in one or both knees. More...
Participants had 24 weeks of treatment with 1,500 mg glucosamine hydrochloride in beverage form or a placebo beverage. The primary outcome was decreased worsening of cartilage damage in all knees identified by magnetic resonance imaging (MRI). Secondary outcomes included change in bone marrow lesions (BMLs) in all knees and excretion of urinary C-terminal cross-linking telopeptide of type II collagen (CTX-II).

The results showed that throughout the trial there was deterioration in cartilage as seen on MRI in only 1.41% of knee subregions—less than the researchers expected. The secondary outcome, urinary excretion CTX-II, a marker of cartilage deterioration, showed no statistically significant difference between groups, although a slight improvement was seen among controls. There also was no difference for patient-reported pain or function on the Western Ontario and McMaster Universities (WOMAC) scales, or in the rates of adverse events. The study was published on March 10, 2014, in Arthritis & Rheumatology.

“Although tempting to say that no advantage to glucosamine was shown and even some evidence that it was worse than placebo, we need to temper our interpretation because of the low rate of progression, as this means the study did not have adequate power to detect even a relatively large difference between treatment and placebo,” said Allen Sawitzke, MD, of the University of Utah. “It suggests to me that this remains an unresolved issue that requires a larger and/or longer study even with MRI-based measurement approaches.”

Glucosamine is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids. It is part of the structure of the polysaccharides chitosan and chitin, which compose the exoskeletons of crustaceans and other arthropods, as well as the cell walls of fungi and many higher organisms. Since glucosamine is a precursor for glycosaminoglycans, and glycosaminoglycans are a major component of joint cartilage, some had hoped that supplemental glucosamine could beneficially influence cartilage structure, and alleviate OA.

Related Links:

University of Utah
University of Arizona



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Mammography System (Analog)
MAM VENUS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.